Christopher Missling - Jan 2, 2024 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Role: President and CEO, Director
Signature: /s/Christopher Missling
Stock symbol: AVXL
Transactions as of: Jan 2, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/12/2024, 08:00 PM
Previous filing: Jun 30, 2023
Next filing: Apr 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVXL	Stock Option (Right to Buy)	Award	$0	-125K	-50%	$0.00	125K	Jan 2, 2024	Common Stock	125K	$10.09	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Christopher Missling is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

Content

On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.